SynthesisFrontiers in endocrinology2026
Placental programming of metabolic diseases: molecular pathways from maternal pregnancy complications to offspring metabolic risk.
Synthesis in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The placenta is increasingly recognized as a dynamic regulatory organ that translates both maternal and paternal physiological and pathological states into developmental signals into developmental signals shaping offspring health across the lifespan. In the context of maternal metabolic and obstetric complications, placental function extends far beyond the regulation of fetal growth, influencing key aspects of development including endocrine set points, nutrient allocation, inflammatory responses, vascular adaptation, and molecular programming across fetal organs. Results: This review examines how maternal conditions -such as obesity, gestational diabetes mellitus (GDM), hypertensive disorders of pregnancy, undernutrition, micronutrient imbalance, and maternal inflammatory stress -induce structural, endocrine, vascular, metabolic, and epigenetic alterations in the placenta. We further explore how these changes disrupt critical molecular pathways, including nutrient sensing and transport, oxidative stress responses, mitochondrial function, angiogenesis and glucocorticoid signaling, immune regulation, and gene expression. A central focus is the convergence of placental mechanisms across diverse maternal disorders, leading to shared offspring phenotypes such as insulin resistance, increased adiposity, dyslipidemia, impaired glucose regulation, altered appetite control, and elevated risk of cardiometabolic disease later in life. Conclusion: Additionally, we address sex-specific placental adaptations, fetal tissue vulnerability, and the translational potential of placental biomarkers and omics-based approaches supported by mechanistic experimental models. By positioning the placenta as the primary biological interface linking maternal complications to offspring susceptibility to endocrine and complex metabolic diseases, this review provides an integrated framework for understanding developmental programming in metabolic health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.